Accéder au contenu
Merck

Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release.

Addiction biology (2013-06-15)
Sarah Bradbury, Judith Bird, Joyce Colussi-Mas, Melanie Mueller, George Ricaurte, Susan Schenk
RÉSUMÉ

The current study aimed to elucidate the role of pharmacokinetic (PK) parameters and neurotransmitter efflux in explaining variability in (±) 3, 4-methylenedioxymethamphetamine (MDMA) self-administration in rats. PK profiles of MDMA and its major metabolites were determined after the administration of 1.0 mg/kg MDMA (iv) prior to, and following, the acquisition of MDMA self-administration. Synaptic levels of 5-hydroxytryptamine (5HT) and dopamine (DA) in the nucleus accumbens were measured following administration of MDMA (1.0 and 3.0 mg/kg, iv) using in vivo microdialysis and compared for rats that acquired or failed to acquire MDMA self-administration. Effects of the 5HT neurotoxin, 5,7 dihydroxytryptamine (5, 7-DHT), on the acquisition of MDMA and cocaine self-administration were also determined. In keeping with previous findings, approximately 50% of rats failed to meet a criterion for acquisition of MDMA self-administration. The PK profiles of MDMA and its metabolites did not differ between rats that acquired or failed to acquire MDMA self-administration. MDMA produced more overflow of 5HT than DA. The MDMA-induced 5HT overflow was lower in rats that acquired MDMA self-administration compared with those that did not acquire self-administration. In contrast, MDMA-induced DA overflow was comparable for the two groups. Prior 5,7-DHT lesions reduced tissue levels of 5HT and markedly increased the percentage of rats that acquired MDMA self-administration and also decreased the latency to acquisition of cocaine self-administration. These data suggest that 5HT limits the initial sensitivity to the positively reinforcing effects of MDMA and delays the acquisition of reliable self-administration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chlorure de magnésium solution, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
Chlorure de magnésium, anhydrous, ≥98%
Sigma-Aldrich
Sodium metabisulfite, ReagentPlus®, ≥99%
Sigma-Aldrich
Sodium metabisulfite, reagent grade, 97%
Sigma-Aldrich
Chlorure de magnésium, powder, <200 μm
Sigma-Aldrich
Sodium metabisulfite, puriss. p.a., ACS reagent, reag. Ph. Eur., dry, 98-100.5%
Sigma-Aldrich
Sodium metabisulfite, puriss., meets analytical specification of Ph. Eur., BP, NF, FCC, E223, dry, 97-100.5%
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, 2 M in H2O
Sigma-Aldrich
Chlorure de magnésium, BioReagent, suitable for insect cell culture, ≥97.0%
Sigma-Aldrich
Chlorure de magnésium solution, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
Chlorure de magnésium, AnhydroBeads, −10 mesh, 99.9% trace metals basis
Sigma-Aldrich
4-Methylcatechol, ≥95%
Sigma-Aldrich
Chlorure de magnésium, AnhydroBeads, −10 mesh, 99.99% trace metals basis
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, ~1 M in H2O
Supelco
Sodium Metabisulfite, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Chlorure de magnésium solution, 0.1 M
Sigma-Aldrich
Sodium metabisulfite, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
USP
Sodium metabisulfite, United States Pharmacopeia (USP) Reference Standard
Supelco
Sodium metabisulfite, analytical standard
Sigma-Aldrich
Sodium metabisulfite, tested according to Ph. Eur.
Sigma-Aldrich
Chlorure de magnésium solution, BioUltra, for molecular biology, ~0.025 M in H2O